Announced details
Treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)
Statistically significant improvement in the primary endpoint versus the control app (specific figures: Not disclosed)
ASKA Pharmaceutical and SUSMED conducted specified clinical research jointly with Professor Ogawa Mariko (小川真理子) of Fukushima Medical University. In September 2023, ASKA Pharmaceutical and SUSMED entered into an agreement covering the research and development and sale of therapeutic apps in the field of obstetrics and gynecology.
The medical support center of the public university corporation to which Professor Ogawa Mariko (小川真理子) belongs. Location, representative, capital and year established: Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Clinical Research Submission and Disclosure System (jRCT: Japan Registry of Clinical Trials)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Therapeutic app for PMS and PMDD |
| Counterparty | Public University Corporation Fukushima Medical University, Fukushima Center for Children and Women's Health Support |
| Counterparty overview | The medical support center of the public university corporation to which Professor Ogawa Mariko (小川真理子) belongs. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | ASKA Pharmaceutical and SUSMED conducted specified clinical research jointly with Professor Ogawa Mariko (小川真理子) of Fukushima Medical University. In September 2023, ASKA Pharmaceutical and SUSMED entered into an agreement covering the research and development and sale of therapeutic apps in the field of obstetrics and gynecology. |
| Contract Date | September 2023 (agreement between ASKA Pharmaceutical and SUSMED,Inc. concerning research and development and sales) |
| Applicable area | Treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) |
| Quantitative Effects | Statistically significant improvement in the primary endpoint versus the control app (specific figures: Not disclosed) |
| Source | Clinical Research Submission and Disclosure System (jRCT: Japan Registry of Clinical Trials) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the aim is to provide a new treatment option for PMS and PMDD and contribute to the advancement of medicine.